dm+d

Unassigned

New Medicines

Type 2 diabetes mellitus

Information

New molecular entity
Hanmi
Hanmi

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A long-acting exendin 4 (exenatide) analogue and glucagon-like peptide-1 (GLP-1) agonist
Currently 3.8 million people in the UK are diagnosed with diabetes (90% type 2), and it is estimated that a further 1 million people with type 2 diabetes have not yet been diagnosed [5].
Type 2 diabetes mellitus
Subcutaneous injection

Type 2 diabetes mellitus; prevention of cardiac events in those with high cardiovascular risk

Information

Licence extension / variation
Hanmi
Hanmi

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A long-acting exendin 4 (exenatide) analogue and glucagon-like peptide-1 (GLP-1) agonist
Currently 3.8 million people in the UK are diagnosed with diabetes (90% type 2), and it is estimated that a further 1 million people with type 2 diabetes have not yet been diagnosed. People with diabetes account for one quarter to one third of hospital admissions for cardiovascular disease [4,5].
Type 2 diabetes mellitus; prevention of cardiac events in those with high cardiovascular risk
Subcutaneous injection